Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.34 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.34 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6680629 | 0.91 | KMT2A (0.40) | MAPT | |
| SCHEMBL6834783 | 0.90 | TSHR (0.40) | TSHR | |
| SCHEMBL6831785 | 0.89 | KDM4E (0.36) | MRGPRX4 | |
| SCHEMBL6835347 | 0.89 | RXRA (0.40) | ALDH1A1MRGPRX4NR4A2MAPT | |
| SCHEMBL6835570 | 0.88 | GRK6 (0.34) | ALDH1A1TSHR | |
| SCHEMBL6835278 | 0.87 | KDM5A (0.35) | TSHRMRGPRX4 | |
| SCHEMBL6837169 | 0.82 | NR4A2 (0.40) | ALDH1A1NR4A2MAPT | |
| SCHEMBL6834729 | 0.82 | TP53 (0.44) | MAPT | |
| SCHEMBL6831721 | 0.80 | MAPT (0.47) | ALDH1A1MAPT | |
| SCHEMBL6835396 | 0.76 | MRGPRX4 (0.37) | ALDH1A1ALOX15MRGPRX4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | HICKS JAMES LESTER (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP26, MMP9 | ALDH1A1 1202/4885ALOX15 106/4885TSHR 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.